Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3674 - Efficacy of palbociclib plus fulvestrant in advanced Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC) pretreated with everolimus: real-life data from the French Temporary Authorization for Use (TAU) at the Institut de Cancérologie de l’Ouest

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Breast Cancer

Presenters

Pauline Du Rusquec

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

P. Du Rusquec1, C. Palpacuer2, L. Campion2, A. Patsouris3, P. Augereau3, C. Gourmelon1, M. Robert1, L. Dumas4, C. Folliard5, M. Campone1, J. Frenel1

Author affiliations

  • 1 Medical Oncology, Centre Rene Gauducheau, 44800 - Nantes/FR
  • 2 Biostatistics, Centre Rene Gauducheau, 44800 - Nantes/FR
  • 3 Medical Oncology, Centre Paul Papin, 49100 - Angers/FR
  • 4 Pharmacy, Centre Rene Gauducheau, 44800 - Nantes/FR
  • 5 Pharmacy, Centre Paul Papin, 49100 - Angers/FR
More

Resources

Abstract 3674

Background

The CDK4-6 inhibitor palbociclib, combined with hormonal therapy is a new standard of treatment for HR+ Metastatic Breast Cancer. Before the European Medicines Agency approval, a Temporary Authorization for Use (TAU) has been set up in France restricted to patients pretreated with everolimus. We present the efficacy data of this combination in this population.

Methods

Between November 2015 and November 2016, all the patients treated with palbociclib + fulvestrant according to the TAU in our institution were prospectively included. Datas from their medical records and adverse events (AE) were collected.

Results

60 patients received at least one dose of palbociclib in combination with fulvestrant with a median age of 61 years. 50 patients (83.3%) had visceral metastasis and 10 (16.7%) had bone only disease. Patients had received an average of 5.3 lines of treatment before palbociclib initiation, including hormonal therapy (mean = 3.0) and chemotherapy (mean = 2.3). Of note, 28 patients (46.7%) had received fulvestrant previously and all had been pretreated with everolimus. With a median follow-up of 8.1 months, median progression free survival (PFS) was 6.1 months (95% CI, 4.2 to 7.4) and median overall survival was not reached. PFS was the same according to the presence of visceral metastasis or no (HR 1.46 (95% CI, 0.57 to 3.74), p = 0.42). Interestingly, patients treated previously with fulvestrant and subsequently re-challenged with fulvestrant and palbociclib had a PFS of 6.4 months, which was similar to patients who didn’t receive fulvestrant previously (HR = 1.00 (95% CI 0.55 to 1.83), p = 1.00). The most common AE were neutropenia (n = 53), thrombocytopenia (n = 25) and anemia (n = 20). At the time of this analysis (April 2017), 36 patients received a further line of treatment after progression.

Conclusions

In this heavily pretreated population, the association of fulvestrant plus palbociclib provides an interesting median PFS of 6.1 months. Patients previously treated with fulvestrant seem to derive the same magnitude of benefit compared to fulvestrant naive patients.

Clinical trial identification

Legal entity responsible for the study

Institut de Cancérologie de l'Ouest

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.